Q32 Bio (QTTB) Net Income towards Common Stockholders Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,228.66% |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | 31.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.02% |
| Dec 31, 2025 | -16.55% |
| Sep 30, 2025 | 58.01% |
| Jun 30, 2025 | 44.11% |
| Mar 31, 2025 | -1,172.01% |
| Dec 31, 2024 | 25.76% |
| Sep 30, 2024 | -25.40% |
| Jun 30, 2024 | -192.37% |
| Mar 31, 2024 | 115.05% |
| Dec 31, 2023 | 177.01% |
| Sep 30, 2023 | 55.65% |
| Jun 30, 2023 | 79.21% |
| Mar 31, 2023 | -107.38% |
| Dec 31, 2022 | -2.94% |
| Sep 30, 2022 | -3.37% |
| Jun 30, 2022 | 8.40% |
| Mar 31, 2022 | 8,735.88% |
| Dec 31, 2021 | -12.73% |
| Sep 30, 2021 | -8.42% |
| Jun 30, 2021 | 13.70% |
| Mar 31, 2021 | 96.96% |
| Dec 31, 2020 | -23.27% |
| Sep 30, 2020 | 4.71% |
| Jun 30, 2020 | -34.53% |
| Mar 31, 2020 | -48.13% |
| Dec 31, 2019 | -28.64% |
| Sep 30, 2019 | -109.41% |
| Jun 30, 2019 | -111.41% |
| Mar 31, 2019 | -133.45% |
| Dec 31, 2018 | -57.79% |
| Sep 30, 2018 | -116.74% |
| Jun 30, 2018 | -107.00% |
| Mar 31, 2018 | -118.37% |